Skip to main content
BIAF logo

BIAF · bioAffinity Technologies, Inc. · Documents

Track BIAF — free
$1.76 -0.09 (-4.86%)
Market Cap
$3.37M
Shares
1.82M
Volume · Nov 20 16.51K Avg daily vol (63 sessions) 3.6M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $6.16M down 34.2% 10-K filed Mar 16, 2026 Quarterly report FY2026 Q3 Revenue $1.07M down 26.0% 10-Q filed Nov 6, 2026 Latest results CyPath Lung sales rise as revenue falls and loss widens 8-K filed Nov 6, 2026
2026
Nov 19
Current report 8-K
CyPath Lung Records Highest Monthly Testing Volume in October 2026

bioAffinity Technologies reported record CyPath Lung testing volume in October 2026, the highest monthly volume for its noninvasive lung cancer test. Q3 CyPath Lung test unit sales rose 109% year to date over 2025, and ordering physicians increased 89%.

Other events
4 source passages
bioAffinity Technologies reported record testing volume in October. A record number of CyPath Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test CyPath Lung test unit sales in Q3 doubled year to date over 2025, with solid gains in physician utilization and recurring orders. Together, the 109% increase in test unit sales, 89% increase in ordering physicians and 48% growth in orders from existing physicians indicate broader physician adoption and increased repeat utilization. Open the document at this passage
Nov 17
Current report 8-K Events of Nov 11
Record 235 CyPath Lung tests performed in October, up 29%

bioAffinity Technologies reports a record 235 CyPath Lung tests performed in October 2026, up 29% from October 2025, its highest monthly testing volume. October volume was equivalent to approximately 45% of tests performed in Q3 2026.

Other events
3 source passages
today announced that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test. In October 2026, 235 CyPath Lung tests were performed, representing a 29% increase compared with October 2025. October 2026 testing volume was equivalent to approximately 45% of the total number of tests performed in Q3 2026. Open the document at this passage
Nov 6
Current report 8-K
CyPath Lung sales rise as revenue falls and loss widens

bioAffinity Technologies reported that CyPath Lung test unit sales increased 100% through Q3 2026, while third-quarter revenue fell to approximately $1.1 million and net loss widened to approximately $5.3 million from approximately $5.1 million.

Financial results
4 source passages
bioAffinity Technologies, Inc. CyPath Lung test unit sales increased 100% through Q3 compared to the first nine months of 2025. Total revenue for the quarter ended September 30, 2026, was approximately $1.1 million, compared with approximately $1.4 million for the same period in 2025. Net loss for the quarter ended September 30, 2026, was approximately $5.3 million, compared with approximately $5.1 million for the third quarter of 2025. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going-concern doubt remains; cash expected to last through March 2027

bioAffinity Technologies reported a net loss of $12.3 million for the nine months ended September 30, 2026, and management concluded there is substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $2.6 million at September 30, 2026, and $4.6 million as of November 3, 2026, which the company expects will support operations through March 2027.

Revenue $1.07M ▼ 26.0% Net loss $5.28M Diluted EPS -$5.89
Read from the MD&A section
4 source passages
For the nine months ended September 30, 2026 and 2025, we had net losses of $12.3 million and $11.8 million, respectively management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months As of September 30, 2026, we had cash and cash equivalents of $2.6 million. As of November 3, 2026, we had cash and cash equivalents of $4.6 million, which we expect will support our operations through March 2027. Open the document at this passage
Oct 29
Current report 8-K
Joins Battle of the Blues Lung Cancer Event November 5

bioAffinity Technologies will join physicians, patients and healthcare providers at the Lung Cancer Initiative of North Carolina's Battle of the Blues on November 5, 2026. It will share CyPath Lung, a noninvasive lung cancer test, at the event.

Other events
2 source passages
The Company will join others committed to advancing lung cancer awareness, research, and patient advocacy on November 5, 2026, at the event where the results of major trials intended to change physician practice will be presented and providers will learn of actionable thoracic oncology results that can enable them to improve treatment and care of lung cancer patients. will join physicians, patients and other healthcare providers at the Lung Cancer Initiative of North Carolina’s Battle of the Blues Open the document at this passage
Oct 23
Proxy statement DEF 14A
Special meeting vote on warrant share issuances, authorized share cut

bioAffinity Technologies will hold a special stockholder meeting on November 20, 2026, to vote on issuing up to 1,128,272 shares under August 2026 warrants and 980,072 shares under October 2026 warrants. Other proposals would seek authorization for non-public offerings and reduce authorized common stock from 350,000,000 shares to 200,000,000 shares. The Board recommends voting FOR all proposals.

Read from the first part of this long document
6 source passages
Special Meeting of Stockholders to be held on Friday, November 20, 2026, at 8:00 a.m. Central Time To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 1,128,272 shares of our Common Stock issuable upon the exercise of Common Stock purchase warrants To approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 980,072 shares of our Common Stock issuable upon the exercise of Common Stock purchase warrants To seek authorization to issue securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d) To approve the amendment of the Certificate of Incorporation to reduce the total number of authorized shares of our common stock from 350,000,000 shares to 200,000,000 shares The Board recommends that you vote your shares: Open the document at this passage
Oct 15
Current report 8-K
Other events

bioAffinity Technologies will sponsor a CHEST 2026 Learning Theater presentation on October 21, 2026, covering CyPath Lung for pulmonary nodule management and lung cancer risk stratification, plus preliminary research on an investigational asthma and COPD inflammation test.

Oct 13
Current report 8-K
Other events

bioAffinity Technologies will present new data at CHEST 2026 on investigational sputum-based tests designed to characterize lung inflammation and detect protein biomarkers associated with asthma and COPD therapies; a poster is scheduled for October 20, 2026.

Oct 9
Current report 8-K Events of Oct 8
Entered into a material agreement, Unregistered sale of equity, Other events

bioAffinity Technologies, Inc. closed an approximately $4 million offering on October 9, 2026, comprising 116,545 shares, pre-funded warrants for up to 536,836 shares, and warrants for up to 980,072 shares. Net proceeds are for working capital.

Read from the first part of this long document
Oct 8
Current report 8-K
Other events

The Japan Patent Office issued a Notice of Allowance for bioAffinity Technologies covering a method of predicting lung cancer likelihood using the CyPath® Lung test; patent issuance is expected after payment of the applicable issuance fee.

Oct 6
Current report 8-K
Other events

bioAffinity Technologies reported that CyPath Lung sales increased more than 100% through the third quarter of 2026 versus 2025, ordering physicians rose 89% in Q3 2026, and more than 1620 tests were delivered versus 775.

Sep 30
Current report 8-K
Other events

bioAffinity Technologies and AvMEDICAL debuted the first joint exhibition of CyPath Lung to more than 300 physicians, healthcare professionals and VA leaders, intending to expand federal access to the noninvasive lung cancer test.

Sep 29
Proxy statement PRE 14A
Proxy statement

bioAffinity Technologies seeks approval to issue up to 1,128,272 common shares from August 2026 warrants, authorize non-public offerings of up to [10,000,000] shares for $[10,000,000] at discounts up to 35%, and reduce authorized common shares from 350,000,000 to [200,000,000].

Read from the first part of this long document
Sep 22
Current report 8-K
Other events

bioAffinity Technologies will present two CyPath® Lung posters at the 2026 NAVREF Annual Conference, September 27-30, 2026, including data from an enrolling 2,000-patient veteran and military study.

Sep 17
Current report 8-K
Other events AI summary on its way
Sep 9
Current report 8-K Events of Sep 8
Other events AI summary on its way
Sep 3
Current report 8-K
Other events AI summary on its way
Sep 1
Current report 8-K
Other events AI summary on its way
Aug 18
Current report 8-K
Other events AI summary on its way
Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.51M ▲ 19.0% Net loss $3.37M Diluted EPS -$0.64
Jul 27
Current report 8-K
Other events AI summary on its way
Jul 22
Current report 8-K
Other events AI summary on its way
Jul 7
Current report 8-K
Other events AI summary on its way
Jun 30
Current report 8-K
Other events AI summary on its way
Jun 16
Current report 8-K
Other events AI summary on its way
Jun 2
Current report 8-K
Other events AI summary on its way
May 27
Current report 8-K
Other events AI summary on its way
May 12
Current report 8-K
Other events AI summary on its way
May 11
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.35M ▼ 27.1% Net loss $3.63M Diluted EPS -$0.81
Apr 14
Current report 8-K
Other events AI summary on its way
Apr 7
Current report 8-K
Other events AI summary on its way
Apr 1
Current report 8-K
Other events AI summary on its way
Mar 25
Current report 8-K
Other events AI summary on its way
Mar 17
Current report 8-K
Other events AI summary on its way
Showing 1–50 of 199 documents
Key facts CIK 1712762 CUSIP 09076W406 13F (30d) 21 filings 14 filers Visit website Investor relations